Form 4: Pacira BioSciences Director Alethia Young Receives Significant Equity Compensation

Pacira BioSciences, Inc. Director Alethia Young was granted 6,163 restricted stock units and options to purchase 11,279 shares of common stock on June 11, 2025, as part of her compensation.

Summary

• On June 11, 2025, Alethia Young, a Director of Pacira BioSciences, Inc. (PCRX), received equity awards.
• These awards include 6,163 shares of common stock in the form of Restricted Stock Units (RSUs).
• Additionally, she was granted stock options to purchase 11,279 shares of common stock.
• The RSUs and stock options were granted at a price of $0, with the stock options having an exercise price of $24.34 per share.
• Both the RSUs and stock options are scheduled to vest and become exercisable on June 11, 2026, contingent upon Ms. Young's continuous service with the company.
• Following these transactions, Ms. Young directly beneficially owns 11,393 shares of common stock and 11,279 stock options.
• The stock options have an expiration date of June 11, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates ongoing director compensation and retention, aligning interests with shareholders, which is generally viewed favorably. It's not highly positive as it's a routine compensation disclosure rather than a significant operational or financial achievement.

Positives

• The grant of equity awards to Director Alethia Young aligns her interests with those of shareholders, incentivizing long-term performance.
• The awards serve as a retention mechanism, ensuring continued service from a key board member.

Risks

• The vesting of both restricted stock units and stock options is contingent upon Alethia Young's continuous service with Pacira BioSciences, Inc. through June 11, 2026.

Future Outlook

The document primarily details an insider equity grant and does not provide forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the vesting schedule for the granted awards.

Industry Context

This Form 4 filing is a standard disclosure of director compensation in the biotechnology and pharmaceutical industry, where equity grants are a common component of executive and board remuneration designed to align interests with long-term company performance.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a director is a common practice in the U.S. biotechnology and pharmaceutical sectors, aligning with typical compensation structures aimed at retaining talent and incentivizing performance.
• While specific comparable companies or projects are not detailed in this filing, such equity grants are standard across publicly traded companies, including peers like Amgen, Gilead Sciences, or Biogen, which frequently use similar mechanisms for director compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, potentially leading to better long-term performance and value creation.
• Employees: While not directly impacting all employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The restricted stock units and stock options are scheduled to vest on June 11, 2026, contingent on continuous service.
• The stock options will become exercisable on June 11, 2026.
• The stock options will expire on June 11, 2035.

Key Dates

Keywords

Pacira BioSciences, PCRX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Alethia Young, Biotechnology, Pharmaceuticals